Julian D Gillmore
Overview
Explore the profile of Julian D Gillmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
273
Citations
9305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Folkvaljon F, Gertz M, Gillmore J, Khella S, Masri A, Maurer M, et al.
Muscle Nerve
. 2024 Nov;
71(1):96-107.
PMID: 39552102
Introduction/aims: The degree of change in neuropathic impairment and quality of life (QoL) that is clinically meaningful to patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is not established. This...
12.
Ioannou A, Razvi Y, Porcari A, Rauf M, Martinez-Naharro A, Venneri L, et al.
JAMA Cardiol
. 2024 Nov;
10(1):50-58.
PMID: 39550765
Importance: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of...
13.
Razvi Y, Judge D, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, et al.
Circ Heart Fail
. 2024 Oct;
17(12):e012135.
PMID: 39465243
No abstract available.
14.
Fontana M, Gillmore J, Verona G
JACC Basic Transl Sci
. 2024 Oct;
9(9):1101-1103.
PMID: 39444933
No abstract available.
15.
Netti L, Ioannou A, Martinez-Naharro A, Razvi Y, Porcari A, Venneri L, et al.
Eur J Heart Fail
. 2024 Oct;
PMID: 39422337
Aims: Cardiac amyloidosis (CA) is characterized by deposition of amyloid fibrils within the extracellular space, causing disarray of the myocardial structure and capillary architecture. This study aims to characterize the...
16.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, et al.
Amyloid
. 2024 Sep;
31(4):353-355.
PMID: 39311543
No abstract available.
17.
Fontana M, Berk J, Gillmore J, Witteles R, Grogan M, Drachman B, et al.
N Engl J Med
. 2024 Aug;
392(1):33-44.
PMID: 39213194
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. Methods: In this double-blind, randomized...
18.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al.
JAMA Cardiol
. 2024 Aug;
9(11):982-989.
PMID: 39167388
Importance: Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless...
19.
Kwok C, Choy C, Pinney J, Townend J, Whelan C, Fontana M, et al.
ESC Heart Fail
. 2024 Jul;
11(6):3901-3910.
PMID: 39041492
Aims: The efficacy of beta-blockers in cardiac amyloidosis (CA) is unclear, and concerns persist that neurohormonal blockade could worsen symptoms of heart failure. We aimed to assess whether beta-blocker therapy...
20.
Nitsche C, Ioannou A, Patel R, Razvi Y, Porcari A, Rauf M, et al.
Eur J Heart Fail
. 2024 Jun;
26(9):2008-2012.
PMID: 38922779
Aims: Transthyretin cardiac amyloidosis (ATTR-CA) is stratified into prognostic categories using the National Amyloidosis Centre (NAC) staging system. The aims of this study were to further expand the existing NAC...